Diabetes
Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials
Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.
Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials
Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management
Novo Nordisk Unveils Enhanced Cardiovascular Benefits of Semaglutide in Post-Hoc Analysis
Semaglutide, Cardiovascular Outcomes, Obesity, Type 2 Diabetes, Novo Nordisk, Post-Hoc Analysis
Semaglutide and Mental Health: A Complex Relationship
semaglutide, mental health, suicidal ideation, GLP-1 drugs, weight loss, diabetes
Alaskans Can Virtually Manage Diabetes Risk for Free with Omada Health
Omada Health, Diabetes Management, Virtual Chronic Care, Alaska, Free Program
Lilly’s Tirzepatide Demonstrates Significant Reduction in Diabetes Risk and Sustained Weight Loss in Overweight Adults
tirzepatide, diabetes risk reduction, sustained weight loss, overweight adults, pre-diabetes, obesity, Eli Lilly, Mounjaro, Zepbound
Lexicon Pharmaceuticals Reduces Workforce by 50% to Focus on Diabetes Drug
Lexicon Pharmaceuticals, workforce reduction, diabetes drug, restructuring, Zynquista
Eli Lilly’s Mounjaro and Zepbound Return to Stock After Extended Shortage, FDA Announces
Eli Lilly, Mounjaro, Zepbound, FDA, drug shortage, weight loss medication, diabetes medication
Sanofi Invests €1.3 Billion in Next-Generation Insulin Facility in Frankfurt
Sanofi, insulin facility, Frankfurt, diabetes treatment, next-generation insulin, €1.3 billion investment
Sanofi Invests €1.3 Billion in New Insulin Manufacturing Plant in Frankfurt
Sanofi, insulin manufacturing, Frankfurt, €1.3 billion, BioCampus, digital solutions, diabetes patients, European supply chain